Quantification of plasma Epstein-Barr virus DNA for assessing treatment response in a patient with plasmablastic lymphoma

Ann Hematol. 2012 May;91(5):789-791. doi: 10.1007/s00277-011-1313-1. Epub 2011 Sep 1.

Authors

Man Fai Law^{1

2}, Wai Lun Poon³, Kwan Shun Ng⁴, Hay Nun Chan⁵, Ho Kei Lai⁵, Chun Yin Ha⁵, Celia Ng⁵, Yiu Ming Yeung⁵, Sze Fai Yip⁵

Affiliations

¹ Department of Medicine, Tuen Mun Hospital, Hong Kong, China. [email protected].
² Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. [email protected].
³ Department of Radiology, Tuen Mun Hospital, Hong Kong, China.
⁴ Department of Pathology, Tuen Mun Hospital, Hong Kong, China.
⁵ Department of Medicine, Tuen Mun Hospital, Hong Kong, China.

PMID: 21881823
DOI: 10.1007/s00277-011-1313-1

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biopsy
Cyclophosphamide / therapeutic use
DNA, Viral / blood*
Doxorubicin / therapeutic use
Epstein-Barr Virus Infections / virology*
Herpesvirus 4, Human / genetics*
Herpesvirus 4, Human / isolation & purification
Humans
Lymph Nodes / pathology
Lymphoma, B-Cell / diagnosis
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / virology*
Male
Middle Aged
Prednisone / therapeutic use
Vincristine / therapeutic use
Viral Load

Substances

DNA, Viral
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol